AIDS Clinical Trials Group 5197: A Placebo‐Controlled Trial of Immunization of HIV‐1–Infected Persons with a Replication‐Deficient Adenovirus Type 5 Vaccine Expressing the HIV‐1 Core Protein
The Journal of Infectious Diseases2010Vol. 202(5), pp. 705–716
Citations Over TimeTop 11% of 2010 papers
Robert T. Schooley, John Spritzler, Hongying Wang, Michael M. Lederman, Diane V. Havlir, Daniel R. Kuritzkes, Richard B. Pollard, Cathy Battaglia, Michael Robertson, Devan V. Mehrotra, Danilo R. Casimiro, Kara S. Cox, Barbara Schock
Abstract
The vaccine was generally safe and well tolerated. Despite a trend favoring viral suppression among vaccine recipients, differences in HIV-1 RNA levels did not meet the prespecified level of significance. Induction of HIV-1 gag-specific CD4 cells correlated with control of viral replication in vivo. Future immunogenicity studies should require a substantially higher immunogenicity threshold before an ATI is contemplated.
Related Papers
- → HIV RNA level in early infection is predicted by viral load in the transmission source(2010)70 cited
- → V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers(2019)34 cited
- → V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers(2019)17 cited
- → Reverse Transcriptase Viral Load Correlates with RNA in SIV/SHIV-Infected Macaques(2006)4 cited
- Predictors of Willingness of Participate in HIV Vaccine Trials among(2014)